Loading...
Market
How many competitors will enter Fabry gene therapy market by end of 2025?
2
Resolution / Starting Odds
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Industry reports and press releases from competing biotech companies
Story
Sangamo Therapeutics Aligns with FDA for Accelerated Approval of ST-920 Gene Therapy for Fabry Disease by 2025
Oct 22, 2024, 12:12 PM
Sangamo Therapeutics announced that it has reached an agreement with the U.S. FDA on an Accelerated Approval pathway for its ST-920 gene therapy product candidate for the treatment of Fabry disease. This alignment is expected to accelerate the potential approval timeline by approximately three years, with a Biologics License Application (BLA) submission anticipated in the second half of 2025. The FDA's decision is a significant step forward for Sangamo's efforts in addressing this rare disease.
View original story
Similar markets
No new competitors • 25%
1-2 new competitors • 25%
3-4 new competitors • 25%
5+ new competitors • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
CRISPR Therapeutics • 25%
Intellia Therapeutics • 25%
Beam Therapeutics • 25%
Other • 25%
Positive • 33%
Neutral • 33%
Negative • 34%
Company A exceeds $10 billion • 25%
Company B exceeds $10 billion • 25%
Both companies exceed $10 billion • 25%
Neither company exceeds $10 billion • 25%
United States only • 25%
United States and European Union • 25%
United States, European Union, and Japan • 25%
Other combinations or none • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Yes • 33%
No • 34%
Top 3 but not best-selling • 33%
Pfizer • 25%
Ionis Pharmaceuticals • 25%
Eidos Therapeutics • 25%
Other • 25%